A commentary on the use of pharmacoenhancers in the pharmaceutical industry and the implication for DMPK drug discovery strategies

References

• Amin ML. 2013. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights. 7:27–34.
   PubMedGoogle Scholar
• Badman ER, Beardsley RL, Liang Z, Bansal S. 2010. Accelerating high quality bioanalytical LC/MS/MS assays using fused-core columns. J Chrom B. 878(25):2307–2313.
   PubMed Web of Science ®Google Scholar
• Benet LZ, Hoener BA. 2002. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 71(3):115–121.
   PubMed Web of Science ®Google Scholar
• Bent RE, Hwang T, Meyer JM, Rao S. 2021. Management of pseudobulbar affect with fluoxetine and dextromethorphan. J Clin Psychopharmacol. 41(5):601–603.
   PubMed Web of Science ®Google Scholar
• Ballard P, Brassil P, Bui KH, Dolgos H, Petersson C, Tunek A, Webborn PJH. 2012. The right compound in the right assay at the right time: an integrated discovery DMPK strategy. Drug Metab Rev. 44(3):224–252.
   PubMed Web of Science ®Google Scholar
• Barry M, Gibbons S, Back D, Mulcahy F. 1997. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 32(3):194–209.
   PubMed Web of Science ®Google Scholar
• Bhal SK, Kassam K, Peirson IG, Pearl GM. 2007. The rule of five revisited: applying *Log D in place of Log P in drug-likeness filters. Mol Pharm. 4(4):556–560.
   PubMed Web of Science ®Google Scholar
• Caldwell GW, Ritchie DM, Masucci JA, Hageman W, Cotto C, Hall J, Hasting B, Jones W. 2005. The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens. Eur J Drug Metab Pharmacokinet. 30(1–2):75–83.
   PubMed Web of Science ®Google Scholar
• Capello S, Henderson L, DeGrazia F, Liberato D, Garland W, Town C. 1990. The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam. Drug Metab Dispos. 18(2):190–196.
   PubMed Web of Science ®Google Scholar
• Congreve M, Aharony D, Albert J, Callaghan O, Campbell J, Carr RAE, Chessari G, Cowan S, Edwards PD, Frederickson M, et al. 2007. Application of fragment screening by x-ray crystallography to the discovery of aminopyridines as inhibitors of β-secretase. J Med Chem. 50(6):1124–1132.
   PubMed Web of Science ®Google Scholar
• Cruz MP. 2013. Nuedexta for the treatment of pseudobulbar affect. P T. 38(6):325–328.
   PubMedGoogle Scholar
• Dahlin JL, Walters MA. 2014. The essential roles of chemistry in high-throughput screening triage. Future Med Chem. 6(11):1265–1290.
   PubMed Web of Science ®Google Scholar
• Davies TG, van Montfort RLM, Williams G, Jhoti H. 2006. Pyramid: an integrated platform for fragment-based drug discovery. Methods Princ Med Chem. 34:193–214.
   Google Scholar
• DeCorte BL. 2020. Evolving outsourcing landscape in pharma r&d: different collaborative models and factors to consider when choosing a contract research organization. J Med Chem. 63(20):11362–11367.
   PubMed Web of Science ®Google Scholar
• Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, Ballard P. 2016. Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos. 44(8):1201–1212.
   PubMed Web of Science ®Google Scholar
• Dirix L, Swaisland H, Verheul HMW, Rottey S, Leunen K, Jerusalem G, Rolfo C, Nielsen D, Molife LR, Kristeleit R, et al. 2016. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studies. Clin Ther. 38(10):2286–2299.
   PubMed Web of Science ®Google Scholar
• Distefano M, Scambia G, Ferlini C, Gaggini C, Vincenzo RD, Riva A, Bombardelli E, Ojima I, Fattorossi A, Panici PB, et al. 1997. Anti-proliferative activity of a new class of taxanes (14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int J Cancer. 72(5):844–850.
   PubMed Web of Science ®Google Scholar
• Doak BC, Over B, Giordanetto F, Kihlberg J. 2014. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem Biol. 21(9):1115–1142.
   PubMed Web of Science ®Google Scholar
• de Esch IJP, Erlanson DA, Jahnke W, Johnson CN, Walsh L. 2022. Fragment-to-lead medicinal chemistry publications in 2020. J Med Chem. 65(1):84–99.
   PubMed Web of Science ®Google Scholar
• Du Souich P, Fradette C. 2011. The effect and clinical consequences of hypoxia on cytochrome P450, membrane carrier proteins activity and expression. Expert Opin Drug Metab Toxicol. 7(9):1083–1100.
   PubMed Web of Science ®Google Scholar
• Eng H, Dantonio AL, Kadar EP, Obach RS, Di L, Lin J, Patel NC, Boras B, Walker GS, Novak JJ, et al. 2022. Disposition of nirmatrelvir, an orally bioavailable inhibitor of SARS-CoV-2 3C-like protease, across animals and humans. Drug Metab Dispos. 50(5):576–590.
   PubMed Web of Science ®Google Scholar
• Erlanson DA, Fesik SW, Hubbard RE, Jahnke W, Jhoti H. 2016. Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov. 15(9):605–619.
   PubMed Web of Science ®Google Scholar
• Ferraris D, Duvall B, Delahanty G, Mistry B, Alt J, Rojas C, Rowbottom C, Sanders K, Schuck E, Huang KC, et al. 2014. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. J Med Chem. 57(6):2582–2588.
   PubMed Web of Science ®Google Scholar
• Ferry DR, Traunecker H, Kerr DJ. 1996. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer. 32A(6):1070–1081.
   PubMed Web of Science ®Google Scholar
• Finlay MRV, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, et al. 2014. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem. 57(20):8249–8267.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Hirsch JS, Nair V. 2022. Special considerations for paxlovid treatment among transplant recipients with SARS-CoV-2 infection. Am J Kidney Dis. 79(4):480–482.
   PubMed Web of Science ®Google Scholar
• Foisy MM, Yakiwchuk EM, Hughes CA. 2008. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 42(7):1048–1059.
   PubMed Web of Science ®Google Scholar
• Galetin A, Clarke SE, Houston JB. 2002. Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 30(12):1512–1522.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, Odenike O, DeZern AE, Yee K, Busque L, et al. 2020. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 136(6):674–683.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Dao K-H, Deeg HJ, Patel PA, Sabloff M, et al. 2019. Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3sStudy (ASCERTAIN study) of an oral hypomethylating agent ASTX727 (cedazuridine/decitabine) compared to IV decitabine. Blood. 134(Supplement_1):846–846.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. 2008. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 83(2):234–242.
   PubMed Web of Science ®Google Scholar
• Gore SD, Jones C, Kirkpatrick P. 2006. Decitabine. Nat Rev Drug Discov. 5(11):891–892.
   PubMed Web of Science ®Google Scholar
• Grainger R, Heightman TD, Ley SV, Lima F, Johnson CN. 2019. Enabling synthesis in fragment-based drug discovery by reactivity mapping: photoredox-mediated cross-dehydrogenative heteroarylation of cyclic amines. Chem Sci. 10(8):2264–2271.
   PubMed Web of Science ®Google Scholar
• Hammer H, Schmidt F, Marx-Stoelting P, Pötz O, Braeuning A. 2021. Cross-species analysis of hepatic cytochrome P450 and transport protein expression. Arch Toxicol. 95(1):117–133.
   PubMed Web of Science ®Google Scholar
• Hann MM. 2011. Molecular obesity, potency and other addictions in drug discovery. Med Chem Commun. 2(5):349–355.
   Web of Science ®Google Scholar
• Hann MM, Keserü GM. 2012. Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat Rev Drug Discov. 11(5):355–365.
   PubMed Web of Science ®Google Scholar
• Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. 2000. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 28(10):1176–1183.
   PubMed Web of Science ®Google Scholar
• Hsu A, Granneman GR, Bertz RJ. 1998. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 35(4):275–291.
   PubMed Web of Science ®Google Scholar
• Huang Z. 2011. Impact of impurities on IC50 values of P450 inhibitors. Drug Metab Lett. 5(3):156–162.
   PubMedGoogle Scholar
• Hull MW, Montaner JSG. 2011. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med. 43(5):375–388.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Walker GS, Wienkers LC. 2003. Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 16(4):450–459.
   PubMed Web of Science ®Google Scholar
• Jhoti H. 2008. Fragment-based drug discovery using rational design. Ernst Schering Found Symp Proc. 2007(3):169–185.
   Google Scholar
• Johnson CN, Ahn JS, Buck IM, Chiarparin E, Day JEH, Hopkins A, Howard S, Lewis EJ, Martins V, Millemaggi A, et al. 2018. A fragment-derived clinical candidate for antagonism of X-linked and cellular inhibitor of apoptosis proteins: 1-(6-[(4-fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-b]pyridin-1-yl)-2-[(2R,5R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660). J Med Chem. 61(16):7314–7329.
   PubMed Web of Science ®Google Scholar
• Kacevska M, Robertson GR, Clarke SJ, Liddle C. 2008. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol. 4(2):137–149.
   PubMed Web of Science ®Google Scholar
• Kang JS, Lee MH. 2009. Overview of therapeutic drug monitoring. Korean J Intern Med. 24(1):1–10.
   PubMedGoogle Scholar
• Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, et al. 2011. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res. 17(3):569–580.
   PubMed Web of Science ®Google Scholar
• Kempf DJ, Sham HL, Marsh KC, Flentge CA, Betebenner D, Green BE, McDonald E, Vasavanonda S, Saldivar A, Wideburg NE, et al. 1998. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J Med Chem. 41(4):602–617.
   PubMed Web of Science ®Google Scholar
• Kerns EH. 2013. Pharmaceutical profiling case study in disruption. ACS Med Chem Lett. 4(2):150–152.
   PubMed Web of Science ®Google Scholar
• Kim N, Norsworthy KJ, Subramaniam S, Chen H, Manning ML, Kitabi E, Earp J, Ehrlich LA, Okusanya OO, Vallejo J, et al. 2022. FDA approval summary: decitabine and cedazuridine tablets for myelodysplastic syndromes. Clin Cancer Res. 28:1–6.
   PubMed Web of Science ®Google Scholar
• Kramlinger VM, Dalvie D, Heck CJS, Kalgutkar AS, O'Neill J, Su D, Teitelbaum AM, Totah RA. 2022. Future of biotransformation science in the pharmaceutical industry. Drug Metab Dispos. 50(3):258–267.
   PubMedGoogle Scholar
• Kukal S, Guin D, Rawat C, Bora S, Mishra MK, Sharma P, Paul PR, Kanojia N, Grewal GK, Kukreti S, et al. 2021. Multidrug efflux transporter ABCG2: expression and regulation. Cell Mol Life Sci. 78(21–22):6887–6939.
   PubMed Web of Science ®Google Scholar
• Kwak J-O, Lee SH, Lee GS, Kim MS, Ahn Y-G, Lee JH, Kim SW, Kim KH, Lee MG. 2010. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol. 627(1–3):92–98.
   PubMed Web of Science ®Google Scholar
• Lamb YN. 2022. Nirmatrelvir plus ritonavir: first approval. Drugs. 82(5):585–591.
   PubMed Web of Science ®Google Scholar
• Leong BK, Sabaitis CP, Rop DA, Jeffrey P, Parker TJ, Burton NK, Petry TW, Jolly RA, Cooper MM. 1997. Alterations in the cardiopulmonary effects and pharmacokinetics of a bisphosphonate drug by a cytochrome P-450 inhibitor in conscious rats. J Appl Toxicol. 17(5):279–288.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 23(1–3):3–25.
   Web of Science ®Google Scholar
• Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW, Schot ME, Schellens JH. 2001. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol. 19(4):1160–1166.
   PubMed Web of Science ®Google Scholar
• Manevski N, Troberg J, Svaluto-Moreolo P, Dziedzic K, Yli-Kauhaluoma J, Finel M. 2013. Albumin stimulates the activity of the human UDP-glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the effects are enzyme and substrate dependent. PLoS One. 8(1):e54767.
   PubMed Web of Science ®Google Scholar
• Ma WW, Li JJ, Azad NS, Lam ET, Diamond JR, Dy GK, Opyrchal M, Zhi J, Kramer D, Chan W-K, et al. 2022. A phase Ib study of oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies. Cancer Chemother Pharmacol. 90(1):7–17.
   PubMed Web of Science ®Google Scholar
• Marmell M, Prigot A. 1957. Oral potassium penicillin G combined with probenecid in the treatment of gonorrhea in the male. Am J Med Sci. 233(3):256–258; passim.
   PubMed Web of Science ®Google Scholar
• Meerum Terwogt JM, Malingré MM, Beijnen JH, Ten Bokkel Huinink WW, Rosing H, Koopman FJ, Van Tellingen O, Swart M, Schellens JH. 1999. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res. 5(11):3379–3384.
   PubMed Web of Science ®Google Scholar
• Menear KA, Adcock C, Boulter R, Cockcroft X, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, et al. 2008. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 51(20):6581–6591.
   PubMed Web of Science ®Google Scholar
• Montané EA, Arellano AL, Sanz Y, Roca J, Farré MA. 2018. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol. 84(3):542–552.
   PubMed Web of Science ®Google Scholar
• Montanha MC, Fabrega F, Howarth A, Cottura N, Kinvig H, Bunglawala F, Lloyd A, Denti P, Waitt C, Siccardi M. 2022. Predicting drug-drug interactions between rifampicin and ritonavir-boosted atazanavir using PBPK modelling. Clin Pharmacokinet. 61(3):375–386.
   PubMed Web of Science ®Google Scholar
• Morrissey KM, Wen CC, Johns SJ, Zhang L, Huang SM, Giacomini KM. 2012. The UCSF-FDA TransPortal: a public drug transporter database. Clin Pharmacol Ther. 92(5):545–546.
   PubMed Web of Science ®Google Scholar
• Mortenson PN, Berdini V, O'Reilly M. 2014. Fragment-based approaches to the discovery of kinase inhibitors. Methods Enzymol. 548:69–92.
   PubMed Web of Science ®Google Scholar
• Murray CW, Newell DR, Angibaud P. 2019. A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA. Med Chem Commun. 10(9):1509–1511.
   Web of Science ®Google Scholar
• Murray CW, Verdonk ML, Rees DC. 2012. Experiences in fragment-based drug discovery. Trends Pharmacol Sci. 33(5):224–232.
   PubMed Web of Science ®Google Scholar
• Oganesian A, Redkar S, Taverna P, Joshi-Hangal R, Azab M. 2013. Preclinical data *In cynomolgus (cyn) monkeys of ASTX727, a novel oral hypomethylating agent (HMA) composed of low-dose oral decitabine combined with a novel cytidine deaminase inhibitor (CDAi) E7727. Blood. 122(21):2526–2526.
   Web of Science ®Google Scholar
• Palacharla RC, Uthukam V, Manoharan A, Ponnamaneni RK, Padala NP, Boggavarapu RK, Bhyrapuneni G, Ajjala DR, Nirogi R. 2017. Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro–in vivo extrapolation of hepatic clearance. Eur J Pharm Sci. 101:80–89.
   PubMed Web of Science ®Google Scholar
• Plowright AT, Johnstone C, Kihlberg J, Pettersson J, Robb G, Thompson RA. 2012. Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle. Drug Discov Today. 17(1–2):56–62.
   PubMed Web of Science ®Google Scholar
• Prikis M, Cameron A. 2022. Paxlovid (nirmatelvir/ritonavir) and tacrolimus drug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: a case report. Transplant Proc. 54(6):1557–1560.
   PubMed Web of Science ®Google Scholar
• Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, et al. 2005. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 104(4):682–691.
   PubMed Web of Science ®Google Scholar
• Rowland A, Gaganis P, Elliot D, Mackenzie PI, Knights KM, Miners JO, Miners J. 2007. Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro–in vivo extrapolation. J Pharmacol Exp Ther. 321(1):137–147.
   PubMed Web of Science ®Google Scholar
• Rüdesheim S, Selzer D, Fuhr U, Schwab M, Lehr T. 2022. Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups. CPT Pharmacometrics Syst Pharmacol. 11(4):495–511.
   Google Scholar
• Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P, Chaudhary A, Fife K, Battiato L, Sweeney C, et al. 2004. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res. 10(10):3265–3272.
   PubMed Web of Science ®Google Scholar
• Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, et al. 2019. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 6(4):e194–e203.
   PubMed Web of Science ®Google Scholar
• Schadel M, Wu D, Otton SV, Kalow W, Sellers EM. 1995. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol. 15(4):263–269.
   PubMed Web of Science ®Google Scholar
• Sharma M, Vadhariya A, Chikermane S, Gopinathan S, Chavez-MacGregor M, Giordano SH, Johnson ML, Holmes HA. 2019. Clinical outcomes associated with drug–drug interactions of oral chemotherapeutic agents: a comprehensive evidence-based literature review. Drugs Aging. 36(4):341–354.
   PubMed Web of Science ®Google Scholar
• Shou WZ. 2020. Current status and future directions of high-throughput ADME screening in drug discovery. J Pharm Anal. 10(3):201–208.
   PubMed Web of Science ®Google Scholar
• Shini Rubina SR, Anuba P, Swetha B, Kalala KP, Pm A, Sabarathinam S. 2022. Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: evidence-based review from six databases. Diabetes Metab Syndr. 16(3):102451.
   PubMed Web of Science ®Google Scholar
• Singh RSP, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, Van Eyck L, Pawlak S, Kadar EP, Clark F, et al. 2022. Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir. Clin Pharmacol Ther. 112(1):101–111.
   PubMed Web of Science ®Google Scholar
• Smith DA, Di L, Kerns EH. 2010. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 9(12):929–939.
   PubMed Web of Science ®Google Scholar
• Smolinski MP, Urgaonkar S, Pitzonka L, Cutler M, Lee GW, Suh KH, Lau JYN. 2021. Discovery of encequidar, first-in-class intestine specific P-glycoprotein inhibitor. J Med Chem. 64(7):3677–3693.
   PubMed Web of Science ®Google Scholar
• Soherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. 2004. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos. 32(10):1121–1131.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al. 2013. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 19(2):202–208.
   PubMed Web of Science ®Google Scholar
• Squillace N, Bozzi G, Colella E, Gori A, Bandera A. 2018. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. DDDT. 12:3635–3643.
   PubMed Web of Science ®Google Scholar
• Stahl SM. 2019. Dextromethorphan/bupropion: a novel oral NMDA (N-methyl-d-aspartate) receptor antagonist with multimodal activity. CNS Spectr. 24(5):461–466.
   PubMed Web of Science ®Google Scholar
• Steadman VA. 2018. Drug discovery: collaborations between contract research organizations and the pharmaceutical industry. ACS Med Chem Lett. 9(7):581–583.
   PubMed Web of Science ®Google Scholar
• Strauch K, Lutz U, Bittner N, Lutz WK. 2009. Dose–response relationship for the pharmacokinetic interaction of grapefruit juice with dextromethorphan investigated by human urinary metabolite profiles. Food Chem Toxicol. 47(8):1928–1935.
   PubMed Web of Science ®Google Scholar
• Stringer RA, Weber E, Tigani B, Lavan P, Medhurst S, Sohal B. 2014. 1-Aminobenzotriazole modulates oral drug pharmacokinetics through cytochrome P450 inhibition and delay of gastric emptying in rats. Drug Metab Dispos. 42(7):1117–1124.
   PubMed Web of Science ®Google Scholar
• Sun D, Gao W, Hu H, Zhou S. 2022. Why 90% of clinical drug development fails and how to improve it. Acta Pharm Sin B. 12(7):3049–3062.
   PubMed Web of Science ®Google Scholar
• Tamanini E, Buck IM, Chessari G, Chiarparin E, Day JEH, Frederickson M, Griffiths-Jones CM, Hearn K, Heightman TD, Iqbal A, et al. 2017. Discovery of a potent nonpeptidomimetic, small-molecule antagonist of cellular inhibitor of apoptosis protein 1 (cIAP1) and X-linked inhibitor of apoptosis protein (XIAP). J Med Chem. 60(11):4611–4625.
   PubMed Web of Science ®Google Scholar
• Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, et al. 2008. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA. 105(8):3041–3046.
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 376(9737):235–244.
   PubMed Web of Science ®Google Scholar
• Umehara KI, Huth F, Won CS, Heimbach T, He H. 2018. Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates. Biopharm Drug Dispos. 39(3):152–163.
   PubMed Web of Science ®Google Scholar
• Urgaonkar S, Nosol K, Said AM, Nasief NN, Bu Y, Locher KP, Lau JYN, Smolinski MP. 2022. Discovery and characterization of potent dual P-glycoprotein and CYP3A4 inhibitors: design, synthesis, cryo-EM analysis, and biological evaluations. J Med Chem. 65(1):191–216.
   PubMed Web of Science ®Google Scholar
• Ursu A, Childs-Disney JL, Andrews RJ, O'Leary CA, Meyer SM, Angelbello AJ, Moss WN, Disney MD. 2020. Design of small molecules targeting RNA structure from sequence. Chem Soc Rev. 49(20):7252–7270.
   PubMed Web of Science ®Google Scholar
• van Veelen A, Gulikers J, Hendriks LEL, Dursun S, Ippel J, Smit EF, Dingemans A-MC, van Geel R, Croes S. 2022. Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small lung cancer: the OSIBOOST trial. Lung Cancer. 171:97–102.
   PubMed Web of Science ®Google Scholar
• Vishwanathan K, Dickinson PA, So K, Thomas K, Chen Y-M, De Castro Carpeño J, Dingemans A-MC, Kim HR, Kim J-H, Krebs MG, et al. 2018. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol. 84(6):1156–1169.
   PubMed Web of Science ®Google Scholar
• Vishwanathan K, So K, Thomas K, Bramley A, English S, Collier J. 2019. Absolute bioavailability of osimertinib in healthy adults. Clin Pharmacol Drug Dev. 8(2):198–207.
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, Shader RI. 1998. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 50(9):997–1004.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang Y, Zhang T, Shi L, Geng Z, Xing D. 2022. Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges. J Enzyme Inhib Med Chem. 37(1):1667–1693.
   PubMed Web of Science ®Google Scholar
• Ward RA, Anderton MJ, Ashton S, Bethel PA, Box M, Butterworth S, Colclough N, Chorley CG, Chuaqui C, Cross DAE, et al. 2013. Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J Med Chem. 56(17):7025–7048.
   PubMed Web of Science ®Google Scholar
• Ward GA, Lewis EJ, Ahn JS, Johnson CN, Lyons JF, Martins V, Munck JM, Rich SJ, Smyth T, Thompson NT, et al. 2018. ASTX660, a novel non-peptidomimetic antagonist of cIAP1/2 and XIAP, potently induces TNFa-dependent apoptosis in cancer cell lines and inhibits tumor growth. Mol Cancer Ther. 17(7):1381–1391.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Mayumi K, Nishimura K, Osaki H. 2016. In vivo use of the CYP inhibitor 1-aminobenzotriazole to increase long-term exposure in mice. Biopharm Drug Dispos. 37(6):373–378.
   PubMed Web of Science ®Google Scholar
• Waters L, Marra F, Pozniak A, Cockburn J, Boffito M. 2022. Ritonavir and COVID-19: pragmatic guidance is important. Lancet. 399(10334):1464–1465.
   PubMed Web of Science ®Google Scholar
• Werling LL, Lauterbach EC, Calef U. 2007. Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. Neurologist. 13(5):272–293.
   PubMed Web of Science ®Google Scholar
• Wernevik J, Bergström F, Novén A, Hulthe J, Fredlund L, Addison D, Holmgren J, Strömstedt PE, Rehnström E, Lundböck T. 2020. A fully integrated assay panel for early drug metabolism and pharmacokinetics profiling. Assay Drug Dev Technol. 18(4):157–179.
   PubMed Web of Science ®Google Scholar
• Wu X, Wang J, Tan L, Bui J, Gjerstad E, McMillan K, Zhang W. 2012. In vitro ADME profiling using high-throughput rapidfire mass spectrometry: cytochrome p450 inhibition and metabolic stability assays. J Biomol Screen. 17(6):761–772.
   PubMed Web of Science ®Google Scholar
• Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, Strickley RG, Tsai LK, Stray KM, Wang Y, et al. 2010. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 1(5):209–213.
   PubMed Web of Science ®Google Scholar
• Xu R, Nemes C, Jenkins KM, Rourick RA, Kassel DB, Liu CZ. 2002. Application of parallel liquid chromatography/mass spectrometry for high throughput microsomal stability screening of compound libraries. J Am Soc Mass Spectrom. 13(2):155–165.
   PubMed Web of Science ®Google Scholar
• Ye Z, Tsao H, Gao H, Brummel CL. 2011. Minimizing matrix effects while preserving throughput in LC-MS/MS bioanalysis. Bioanalysis. 3(14):1587–1601.
   PubMed Web of Science ®Google Scholar
• Zelin RK, Petruschke RA. 2014. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 53:4–9.
   Web of Science ®Google Scholar
• Zhang C, Ibrahim PN, Zhang J, Burton EA, Habets G, Zhang Y, Powell B, West BL, Matusow B, Tsang G, et al. 2013. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A. 110(14):5689–5694.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhang J, Gao Y, Li Y, Li Y. 2022. Strategies for targeting undruggable targets. Expert Opin Drug Discov. 17(1):55–69.
   PubMed Web of Science ®Google Scholar